Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CAPR vs ANL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CAPR Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–6 Matrix Metrics)

CAPR Overall Winner 6-Pillar Tally: CAPR 3 – 2 ANL (1 Tie) Matrix Metrics: CAPR 4 – 6 ANL

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over ANL (ANL) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). CAPR carries a Unified Composite Score of 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin), whereas ANL carries 48.3/100 (HOLD) at $9.97 (N/M Forward P/E, -123.5% operating margin).

  • Composite vs. Pillar Nuance: While ANL currently prints a higher short-term Unified Composite Score (48.3/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (4–6 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -123.5% operating margin) and revenue trajectory (-7.9% vs. +178.1% YoY).
  • Technical & Structure Timing Caution: CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3); meanwhile ANL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CAPR vs ANL
CAPR NASDAQ Head-to-Head Winner
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.52β · 152% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.3 · SMA20: $7.79 · SMA50: $8.08
ANL US Equity
ANL
Institutional Equity
$9.97
-6.03% 1D
Market Cap $677.5M
TTM Revenue $18M
Forward P/E N/M
Beta / 30D Vol 2.61β · 79% Vol
Unified Composite Score
48.3 / 100 HOLD
Tech 48.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 44
RSI-14: 44.0 · SMA20: $10.32 · SMA50: $12.93

6-Pillar Scorecard Institutional Category Breakdown (CAPR 3 – 2 ANL)

Columns: Metric · CAPR · ANL
1. Valuation Multiples CAPR
Forward P/E 78.7x N/M
Trailing P/E 78.7x N/M
PEG Ratio 0.38x N/M
EV / Revenue 57.8x 37.5x
2. Growth & Scale ANL
Revenue Growth (YoY) -7.9% +178.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M $18M
Market Cap $595.4M $677.5M
3. Profitability & Quality CAPR
Gross Margin N/A 100.0%
Operating Margin 0.0% -123.5%
Net Profit Margin 0.0% -124.8%
Return on Equity (ROE) -100.5% -20.2%
4. Balance Sheet & Cash Flow ANL
Cash Generation (TTM) -$146M -$22M EBITDA
Cash Flow Margin N/A -119.9% EBITDA Mgn
Net Cash / Leverage $48M Net Debt (0.44x D/E) $3.34 Book/Sh · -20.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAPR
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 637.1% (89th %ile) N/A (N/A)
Put/Call OI Skew 1.57x (Put-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CAPR (4) vs ANL (6)
Institutional Metric CAPR ANL Criterion Row Edge
Market Capitalization
Scale
$595.4M $677.5M Larger Scale ANL
Trailing P/E Ratio
Valuation
78.7x N/M Lower Multiple CAPR
Forward P/E Ratio
Valuation
78.7x N/M Lower Multiple CAPR
Revenue Growth (YoY)
Growth
-7.9% +178.1% Higher Growth ANL
Operating Margin (TTM)
Profitability
0.0% -123.5% Higher Margin CAPR
Net Profit Margin
Profitability
0.0% -124.8% Higher Margin CAPR
Return on Equity (ROE)
Capital Efficiency
-100.5% -20.2% Higher ROE ANL
52-Week Range Position
Momentum
15% ($3–$40) 56% ($1–$17) Stronger Trend ANL
Beta / 30D Volatility
Risk Regime
1.52β · 152% Vol 2.61β · 79% Vol Lower Realized Risk ANL
Unified Institutional Score
Composite Signal
28.0 / 100 (SELL) 48.3 / 100 (HOLD) Higher Composite ANL
Trailing 12M Revenue (USD)
Operating Scale
$11M $18M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.38x PEG · 57.8x EV/Rev N/M PEG · 37.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$146M ($48M Net Debt (0.44x D/E)) -$22M EBITDA ($3.34 Book/Sh · -20.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAPR +35.84 pp
CAPR: +26.23% · ANL: -9.61%
3M Horizon CAPR +49.22 pp
CAPR: +19.63% · ANL: -29.59%
6M Horizon ANL +44.38 pp
CAPR: -70.58% · ANL: -26.2%
1Y Horizon ANL +513.47 pp
CAPR: +46.79% · ANL: +560.26%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CAPR vs ANL. Trailing 12-month operating profitability (CAPR 0.0% vs ANL -123.5%) and valuation multiples (CAPR 78.7x vs ANL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CAPR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-100.5% · 78.7x
ANL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$18M
Gross Margin100.0%
Op. Margin-123.5%
ROE / Fwd P/E-20.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ANL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $677.5M market capitalization and -123.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CAPR vs ANL Key Questions & Quantitative Answers

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over ANL (ANL) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). CAPR carries a Unified Composite Score of 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin), whereas ANL carries 48.3/100 (HOLD) at $9.97 (N/M Forward P/E, -123.5% operating margin). Composite vs. Pillar Nuance: While ANL currently prints a higher short-term Unified Composite Score (48.3/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (4–6 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -123.5% operating margin) and revenue trajectory (-7.9% vs. +178.1% YoY). Technical & Structure Timing Caution: CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3); meanwhile ANL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANL leads the Growth & Scale pillar: CAPR posts -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin), compared with ANL at +178.1% YoY revenue growth and +0.0% YoY earnings growth on $18M TTM revenue (100.0% gross margin, -123.5% operating margin). On trailing 12-month operating scale, CAPR generates $11M in USD-normalized revenue versus $18M for ANL. In operating R&D and SG&A reinvestment, CAPR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANL.

CAPR screens cheaper on headline valuation multiples. CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin), whereas ANL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 37.5x EV/Revenue (-119.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAPR (-100.5% ROE) versus ANL (-20.2% ROE) capital efficiency.

In options market volatility and institutional positioning, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk). By comparison, ANL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.61β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.